603367 辰欣药业
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入2,070,524-6.72%4,462,3494,066,0883,782,5933,674,158
减:营业总成本1,800,516-7.19%3,866,6833,717,6183,536,8143,294,833
    其中:营业成本874,863-11.65%1,839,0241,789,2931,684,6471,570,901
               财务费用(17,184)1.58%(33,671)(27,876)(9,084)3,366
               资产减值损失(37,778)5.58%(73,497)(16,462)(21,297)(28,483)
公允价值变动收益8,425-68.18%(10,375)(3,120)(6,090)23,032
投资收益18,31217.36%44,11818,68072,51373,374
    其中:对联营企业和合营企业的投资收益0-99.95%132(753)4,166411
营业利润290,120-0.11%592,578364,583334,421484,673
利润总额292,0630.46%595,857366,191336,132484,516
减:所得税费用18,347-23.02%70,43013,9202,23047,156
净利润273,7162.56%525,426352,271333,902437,360
减:非控股权益3,40024.25%4,0882,313(245)(1,424)
股东净利润270,3172.33%521,338349,959334,146438,784

市场价值指针
每股收益 (元) *0.6003.45%1.1500.7700.7400.970
每股派息 (元) *0.220--0.4360.3350.3000.256
每股净资产 (元) *12.8266.68%12.64911.76311.15010.590
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容